| Name | Title | Contact Details |
|---|
Brown Physicians, Incorporated (BPI) is a community-based not-for-profit multi-specialty practice group founded and led by faculty affiliated with The Warren Alpert Medical School of Brown University. Our mission is to provide outstanding patient care, exceptional medical education, and groundbreaking advances in research to promote better health for the people of Rhode Island and its surrounding communities. BPI is composed of six foundations, which include Brown Dermatology, Brown Emergency Medicine, Brown Medicine, Brown Neurology, Brown Urology, and University Surgical Associates.
BMR HealthQuest is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Tallahassee Memorial HealthCare is a private, not-for-profit community healthcare system founded in 1948.
Royal Oaks Lifecare Community is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Royal Oaks Lifecare Community is based in Sun City, AZ. You can find more information on Royal Oaks Lifecare Community at www.royaloakslife.com
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.